These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 15377577)

  • 1. Discontinuation of imatinib therapy after achieving a molecular response.
    Cortes J; O'Brien S; Kantarjian H
    Blood; 2004 Oct; 104(7):2204-5. PubMed ID: 15377577
    [No Abstract]   [Full Text] [Related]  

  • 2. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML.
    Branford S; Yeung DT; Ross DM; Prime JA; Field CR; Altamura HK; Yeoman AL; Georgievski J; Jamison BA; Phillis S; Sullivan B; Briggs NE; Hertzberg M; Seymour JF; Reynolds J; Hughes TP
    Blood; 2013 May; 121(19):3818-24. PubMed ID: 23515925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia.
    Bazeos A; Marin D; Reid AG; Gerrard G; Milojkovic D; May PC; de Lavallade H; Garland P; Rezvani K; Apperley JF; Goldman JM; Foroni L; Khorashad JS
    Leukemia; 2010 Jun; 24(6):1243-5. PubMed ID: 20445576
    [No Abstract]   [Full Text] [Related]  

  • 4. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
    Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
    Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-resistance of imatinib mesylate and 17-AAG in imatinib-resistant cells that overexpress BCR-ABL.
    Topaly J; Schad M; Laufs S; Melo JV; Zeller WJ; Fruehauf S
    Br J Haematol; 2003 May; 121(4):672-3. PubMed ID: 12752112
    [No Abstract]   [Full Text] [Related]  

  • 6. Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients.
    Martinelli G; Iacobucci I; Rosti G; Pane F; Amabile M; Castagnetti F; Cilloni D; Soverini S; Testoni N; Specchia G; Merante S; Zaccaria A; Frassoni F; Saglio G; Baccarani M
    Ann Oncol; 2006 Mar; 17(3):495-502. PubMed ID: 16403813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discontinuing imatinib in chronic myeloid leukemia: don't try this at home.
    Mattison R; Larson RA
    Leuk Lymphoma; 2009 Jun; 50(6):868-70. PubMed ID: 19455466
    [No Abstract]   [Full Text] [Related]  

  • 8. The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia.
    Quintás-Cardama A; Kantarjian H; Cortes J
    Leuk Lymphoma; 2007 Apr; 48(4):802-4. PubMed ID: 17454640
    [No Abstract]   [Full Text] [Related]  

  • 9. Beyond Gleevec--the next generation in CML.
    Fricker J
    Eur J Cancer; 2006 Feb; 42(3):275. PubMed ID: 16514710
    [No Abstract]   [Full Text] [Related]  

  • 10. Molecular response in CML: where is the bar?
    Baccarani M; Soverini S
    Blood; 2014 Jul; 124(4):469-71. PubMed ID: 25061165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
    Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
    Wang L; Pearson K; Pillitteri L; Ferguson JE; Clark RE
    Br J Haematol; 2002 Sep; 118(3):771-7. PubMed ID: 12181044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is b3a2 a better prognostic variant in childhood chronic myeloid leukemia?
    Malhotra KP; Sharma CB; Jain J; Grover RK
    J Postgrad Med; 2010; 56(3):221-2. PubMed ID: 20739774
    [No Abstract]   [Full Text] [Related]  

  • 14. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia.
    Wang L; Pearson K; Ferguson JE; Clark RE
    Br J Haematol; 2003 Mar; 120(6):990-9. PubMed ID: 12648069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.
    Chu S; Xu H; Shah NP; Snyder DS; Forman SJ; Sawyers CL; Bhatia R
    Blood; 2005 Mar; 105(5):2093-8. PubMed ID: 15345592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia.
    Donato NJ; Wu JY; Stapley J; Lin H; Arlinghaus R; Aggarwal BB; Shishodia S; Albitar M; Hayes K; Kantarjian H; Talpaz M
    Cancer Res; 2004 Jan; 64(2):672-7. PubMed ID: 14744784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
    Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular monitoring in chronic myeloid leukemia patients who achieve complete cytogenetic remission on imatinib.
    Lin F; Drummond M; O'Brien S; Cervantes F; Goldman J; Kaeda J
    Blood; 2003 Aug; 102(3):1143. PubMed ID: 12869491
    [No Abstract]   [Full Text] [Related]  

  • 19. Chronic myeloid leukemia. Sceptical scientists.
    Druker BJ
    Lancet; 2001 Dec; 358 Suppl():S11. PubMed ID: 11784560
    [No Abstract]   [Full Text] [Related]  

  • 20. In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib.
    Sobrinho-Simões M; Wilczek V; Score J; Cross NC; Apperley JF; Melo JV
    Blood; 2010 Aug; 116(8):1329-35. PubMed ID: 20462961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.